RESUMO
The lifetime risk of breast cancer may approach 80-90% in women who have germline mutations of either of two genes, BRCA1 or BRCA2. A single BRCA1 mutation, 185delAG, has been noted in approximately 20% of Ashkenazi Jewish women with early onset breast cancer and in 0.9% of the Ashkenazi population. We recently detected a 6174delT frameshift mutation in BRCA2 in an hereditary breast cancer kindred of Ashkenazi Jewish ancestry. Here, we investigated the frequency of this mutation in 200 women with early-onset breast cancer. Six of 80 Ashkenazi Jewish women (8%) diagnosed with breast cancer before the age of 42, wer heterozygous for the 6174delT mutation, compared to none of 93 non-Jewish women diagnosed with breast cancer at the same age (P = .005). These cases were ascertained without regard to family history. Two of 27 (7%) additional Jewish families in which the proband was diagnosed with breast cancer at age 42 to 50 and had a family history of breast or ovarian cancer had germline 6174delT mutations. The results of this report suggest that a recurrent mutation of BRCA1 and a recurrent mutation BRCA2 together may account for over a quarter of all early-onset breast cancer in the setting of a personal or family history of ovarian cancer in Ashkenazi Jewish women.
Assuntos
Neoplasias da Mama/genética , Judeus/genética , Proteínas de Neoplasias/genética , Neoplasias Ovarianas/genética , Deleção de Sequência , Fatores de Transcrição/genética , Adulto , Proteína BRCA1 , Proteína BRCA2 , Sequência de Bases , Neoplasias da Mama/epidemiologia , Primers do DNA , Família , Feminino , Marcadores Genéticos , Humanos , Pessoa de Meia-Idade , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Medição de Risco , Fatores de RiscoRESUMO
It is difficult to identify genes that predispose to prostate cancer due to late age at diagnosis, presence of phenocopies within high-risk pedigrees and genetic complexity. A genome-wide scan of large, high-risk pedigrees from Utah has provided evidence for linkage to a locus on chromosome 17p. We carried out positional cloning and mutation screening within the refined interval, identifying a gene, ELAC2, harboring mutations (including a frameshift and a nonconservative missense change) that segregate with prostate cancer in two pedigrees. In addition, two common missense variants in the gene are associated with the occurrence of prostate cancer. ELAC2 is a member of an uncharacterized gene family predicted to encode a metal-dependent hydrolase domain that is conserved among eukaryotes, archaebacteria and eubacteria. The gene product bears amino acid sequence similarity to two better understood protein families, namely the PSO2 (SNM1) DNA interstrand crosslink repair proteins and the 73-kD subunit of mRNA 3' end cleavage and polyadenylation specificity factor (CPSF73).
Assuntos
Cromossomos Humanos Par 17/genética , Proteínas de Neoplasias/genética , Neoplasias da Próstata/genética , Sequência de Aminoácidos , Clonagem Molecular/métodos , DNA Complementar/genética , Efeito Fundador , Ligação Genética , Predisposição Genética para Doença , Genótipo , Humanos , Masculino , Dados de Sequência Molecular , Mutação de Sentido Incorreto , Linhagem , RNA Mensageiro/genética , Análise de Sequência de DNA , Homologia de Sequência de Aminoácidos , UtahRESUMO
Disorders of the Ras/mitogen-activated protein kinase (MAPK) pathway have an overlapping skeletal phenotype (e.g. scoliosis, osteopenia). The Ras proteins regulate cell proliferation and differentiation and neurofibromatosis type 1 (NF1) individuals have osteoclast hyperactivity and increased bone resorption as measured by urine pyridinium crosslinks [pyridinoline (Pyd) and deoxypyridinoline (Dpd)]. Pyd and Dpd are hydroxylysine-derived crosslinks of collagen found in bone and cartilage and excreted in the urine. Dpd is most abundant in bone. The aim of this study was to evaluate if other syndromes of the Ras/MAPK pathway have increased bone resorption, which may impact the skeletal phenotype. Participants were individuals with Noonan syndrome (n = 14), Costello syndrome (n = 21), and cardiofaciocutaneous (CFC) syndrome (n = 14). Pyridinium crosslinks from two consecutive first morning urines were extracted after acid hydrolysis and analyzed by high performance liquid chromatography. Three separate analyses of covariance were performed to compare Pyd, Dpd, and Dpd/Pyd ratio of each group to controls after controlling for age. Data were compared to 99 healthy controls. The Dpd and the Dpd/Pyd ratio were elevated (p < 0.0001) in all three conditions compared to controls suggesting that collagen degradation was predominantly from bone. The data suggest that the Ras/MAPK signal transduction pathway is important in bone homeostasis.
Assuntos
Reabsorção Óssea/patologia , Sistema de Sinalização das MAP Quinases , Proteínas Proto-Oncogênicas p21(ras)/genética , Transdução de Sinais , Absorciometria de Fóton , Adolescente , Adulto , Aminoácidos/urina , Biomarcadores/urina , Densidade Óssea , Reabsorção Óssea/genética , Reabsorção Óssea/urina , Estudos de Casos e Controles , Criança , Pré-Escolar , Cromatografia Líquida de Alta Pressão , Estudos de Coortes , Colágeno/urina , Síndrome de Costello/genética , Síndrome de Costello/patologia , Síndrome de Costello/urina , Análise Mutacional de DNA , Displasia Ectodérmica/genética , Displasia Ectodérmica/patologia , Displasia Ectodérmica/urina , Fácies , Insuficiência de Crescimento/genética , Insuficiência de Crescimento/patologia , Insuficiência de Crescimento/urina , Feminino , Testes Genéticos , Cardiopatias Congênitas/genética , Cardiopatias Congênitas/patologia , Cardiopatias Congênitas/urina , Humanos , Hidrólise , Masculino , Síndrome de Noonan/genética , Síndrome de Noonan/patologia , Síndrome de Noonan/urina , Proteína Tirosina Fosfatase não Receptora Tipo 11/genética , Adulto JovemRESUMO
BACKGROUND: The role of germline and somatic SMARCB1 gene mutations in malignant rhabdoid tumour (MRT) predisposition is well known. Germline SMARCB1 mutations have also recently been identified in a subset of individuals with schwannomatosis. Surprisingly, MRT predisposition and schwannomatosis have never been reported to co-occur in a family. The correlation between genotype and phenotype for mutations in SMARCB1 has not been determined. RESULTS: We have identified a germline 2631 bp duplication that includes exon 6 of SMARCB1 in a unique family with a four generation history of MRT predisposition and schwannomatosis. This duplication segregates with disease in individuals affected with both conditions, linking MRT predisposition and schwannomatosis as components of the same syndrome in this family. CONCLUSION: The unique combination of tumours that result from the duplication described in this report may provide important clues about the mechanisms that influence the phenotype associated with a given SMARCB1 mutation.
Assuntos
Proteínas Cromossômicas não Histona/genética , Proteínas de Ligação a DNA/genética , Duplicação Gênica , Neurilemoma/genética , Tumor Rabdoide/genética , Fatores de Transcrição/genética , Sequência de Bases , Éxons , Família , Genótipo , Mutação em Linhagem Germinativa , Humanos , Dados de Sequência Molecular , Neurilemoma/patologia , Linhagem , Fenótipo , Tumor Rabdoide/patologia , Proteína SMARCB1RESUMO
Loss of heterozygosity data from familial tumors suggest that BRCA1, a gene that confers susceptibility to ovarian and early-onset breast cancer, encodes a tumor suppressor. The BRCA1 region is also subject to allelic loss in sporadic breast and ovarian cancers, an indication that BRCA1 mutations may occur somatically in these tumors. The BRCA1 coding region was examined for mutations in primary breast and ovarian tumors that show allele loss at the BRCA1 locus. Mutations were detected in 3 of 32 breast and 1 of 12 ovarian carcinomas; all four mutations were germline alterations and occurred in early-onset cancers. These results suggest that mutation of BRCA1 may not be critical in the development of the majority of breast and ovarian cancers that arise in the absence of a mutant germline allele.
Assuntos
Neoplasias da Mama/genética , Genes Supressores de Tumor , Mutação em Linhagem Germinativa , Proteínas de Neoplasias/genética , Neoplasias Ovarianas/genética , Fatores de Transcrição/genética , Adulto , Idade de Início , Alelos , Proteína BRCA1 , Sequência de Bases , Cromossomos Humanos Par 17 , Feminino , Predisposição Genética para Doença , Heterozigoto , Humanos , Pessoa de Meia-Idade , Dados de Sequência MolecularRESUMO
A strong candidate for the 17q-linked BRCA1 gene, which influences susceptibility to breast and ovarian cancer, has been identified by positional cloning methods. Probable predisposing mutations have been detected in five of eight kindreds presumed to segregate BRCA1 susceptibility alleles. The mutations include an 11-base pair deletion, a 1-base pair insertion, a stop codon, a missense substitution, and an inferred regulatory mutation. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. This protein contains a zinc finger domain in its amino-terminal region, but is otherwise unrelated to previously described proteins. Identification of BRCA1 should facilitate early diagnosis of breast and ovarian cancer susceptibility in some individuals as well as a better understanding of breast cancer biology.
Assuntos
Neoplasias da Mama/genética , Cromossomos Humanos Par 17 , Genes Supressores de Tumor , Mutação , Proteínas de Neoplasias/genética , Neoplasias Ovarianas/genética , Fatores de Transcrição/genética , Alelos , Processamento Alternativo , Sequência de Aminoácidos , Animais , Proteína BRCA1 , Feminino , Predisposição Genética para Doença , Mutação em Linhagem Germinativa , Haplótipos , Humanos , Escore Lod , Masculino , Dados de Sequência Molecular , Proteínas de Neoplasias/química , Proteínas de Neoplasias/fisiologia , Linhagem , Fenótipo , Fatores de Transcrição/química , Fatores de Transcrição/fisiologia , Dedos de ZincoRESUMO
BACKGROUND: Mutation of a specific, but as yet unidentified, gene BRCA1 on chromosome 17q results in increased susceptibility to breast and ovarian cancer. It is important to know the effects of this gene in terms of the age-specific risks of these cancers and the potential interaction of this gene with other known risk factors. PURPOSE: We performed detailed studies on a large multigenerational family, in which there is known 17q-linked breast and ovarian cancer, in order to characterize the effects of the BRCA1 mutation on development of breast and ovarian cancer. METHODS: Data from the Utah Population Database were used to identify a family (identified as K2082) with a cluster of premenopausal breast cancer and ovarian cancer at any age. Blood samples from 195 members of the family were obtained and these individuals were genotyped for a series of four chromosome 17q polymorphic markers. Information on reproductive history, cancer incidence and treatment, and lifestyle factors was collected on 72 women in the family by questionnaire or through contact with living relatives. RESULTS: Odds in favor of linkage of breast and ovarian cancer in this family to the BRCA1 region of chromosome 17q are greater than 10(8) to 1. The estimated risks for breast or ovarian cancer because of the BRCA1 mutation in this family are 40% by age 50 years and 90% by age 70. No differences between affected and unaffected older BRCA1 gene carriers were observed for a number of known epidemiologic risk factors for these cancers. The gender of the parent from whom the mutant BRCA1 allele was inherited was significantly associated with phenotypic expression (P = .04). A recombinant which places BRCA1 distal to the marker Mfd191 was observed. CONCLUSIONS: Women with the BRCA1 mutation are at increased risk of developing breast and ovarian cancer. In our study population, the mutation appears to confer a lower risk of cancer at younger ages than found in previous studies. Continued interaction with family K2082 will be useful in longitudinal follow-up studies and in studies of the psychosocial implications of providing DNA diagnosis of BRCA1.
Assuntos
Neoplasias da Mama/genética , Cromossomos Humanos Par 17 , Neoplasias Ovarianas/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Sequência de Bases , DNA de Neoplasias/análise , Feminino , Ligação Genética , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Mutação , Linhagem , Fenótipo , Fatores de RiscoRESUMO
A gene called "prohibitin" was isolated as a candidate antiproliferating gene in rat liver cells. We have isolated the human homologue of the rat prohibitin gene and mapped it to chromosome 17q12-21 where a gene responsible for hereditary breast cancer was localized. DNA sequence analysis of 2 exons in this gene in 23 sporadic breast cancers, which showed loss of heterozygosity on the long arm of chromosome 17 or developed in patients 35 years old or younger, identified 4 cases of somatic mutation; 2 of these were missense mutations; 1 showed a 2-base deletion resulting in truncation of the gene product due to a frame shift; the other had a C to T transition in an intron adjacent to an intron-exon boundary. These results suggest that this gene may be a tumor suppressor gene and is associated with tumor development and/or progression of at least some breast cancers.
Assuntos
Neoplasias da Mama/genética , Cromossomos Humanos Par 17 , Genes Supressores , Mutação/genética , Sequência de Aminoácidos , Sequência de Bases , Feminino , Humanos , Dados de Sequência MolecularRESUMO
Colorectal cancer (CRC) has a strong familial component. Candidate genes for colorectal cancer have been identified through mutations in four mismatch repair genes (hMSH2, hMLH1, hPMS1, and hPMS2) and genes that are deleted or mutated in tumors (DCC, APC, and p53). Linkage analysis of candidate loci/regions was performed in 10 kindreds ascertained for common colorectal cancer from the Utah Population Database. Evidence for linkage to candidate genes was assessed using two- or three-point logarithm of the odds ratio scores with markers spanning the region of localization. One kindred is linked to hMSH2 and also fits the criteria for hereditary nonpolyposis colorectal cancer, having early age of onset and high penetrance for CRC. The remaining nine kindreds are unlinked to the candidate genes tested. These kindreds have a later age of onset and a lower penetrance than hereditary nonpolyposis colorectal cancer kindreds. these results indicate that further unmapped susceptibility loci may be responsible for much of the familial aggregation of CRC.
Assuntos
Mapeamento Cromossômico , Neoplasias Colorretais/genética , Família , Heterogeneidade Genética , Escore Lod , Adulto , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Proteínas de Ligação a DNA/genética , Suscetibilidade a Doenças , Feminino , Ligação Genética , Marcadores Genéticos , Humanos , Masculino , Pessoa de Meia-Idade , Mutação/genética , LinhagemRESUMO
A mitochondria-free membrane fraction prepared from rat myometrium accumulated 45Ca2+ in the presence of oxalic acid and ATP. The rate of transport of Ca2+ into the membranous vesicles was increased by greater than 50% in the presence of 3',5'-cyclic AMP, but not by 2',3'-cyclic AMP or 5'AMP. Membrane ATPase activity was stimulated by Mg2+; slight additional stimulation was obtained in the presence of Na+ and K+ but not in the presence of Ca+2. Despite the cyclic AMP sensitivity of membrane ATPase activity, the absence of any effect of inhibitors of Ca2+-transport suggest it has little to do with Ca2+ accumulation by the membranes. Cyclic AMP-induced increase in Ca2+-transport and membrane ATPase activity was duplicated in vivo by incubating uteri in 10(-4)M isoproterenol prior to membrane isolation. Isoproterenol has been previously shown to increase myometrial cyclic AMP levels, and changes in Ca2+-transport by cell membranes in relation to intracellular cyclic AMP levels may be the mechanism through which hormones modulate uterine contractility.
Assuntos
AMP Cíclico/farmacologia , Membranas/metabolismo , Microssomos/metabolismo , Miométrio/metabolismo , Contração Uterina/efeitos dos fármacos , Útero/metabolismo , Adenosina Trifosfatases/metabolismo , Animais , Transporte Biológico Ativo , Cálcio/metabolismo , Cálcio/farmacologia , Castração , Ativação Enzimática , Feminino , Isoproterenol/farmacologia , Cinética , Magnésio/farmacologia , Membranas/efeitos dos fármacos , Membranas/ultraestrutura , Microssomos/efeitos dos fármacos , Microssomos/ultraestrutura , Miométrio/efeitos dos fármacos , Ouabaína/farmacologia , Oxalatos/farmacologia , RatosRESUMO
A technique that can be used to isolate vector/insert junctions from clones in vectors, such as yeast artificial chromosomes and P1s, and to sequence plasmid inserts more rapidly has been developed. A vector primer is combined with single, randomly chosen oligonucleotides in PCRs, to create pools of products. With 12-24 random primers used in separate reactions, a given insert junction can frequently be isolated. For plasmid inserts, multiple products are created that can be sequenced from their random-primed ends to provide internal coverage for a clone. It is often possible to sequence a significant portion of an insert with one set of reactions. The speed and simplicity of the method in each case and its use of existing techniques and reagents make it appealing.
Assuntos
Cromossomos Artificiais de Levedura/genética , Primers do DNA , DNA Recombinante/genética , Vetores Genéticos/genética , Reação em Cadeia da Polimerase/métodos , Análise de Sequência de DNA/métodos , Sequência de Bases , Dados de Sequência MolecularRESUMO
The cytodiagnosis of Pneumocystis carinii (PC) in bronchoalveolar lavage (BAL) fluids has traditionally required a special stain such as Gomori's methenamine silver (GMS) stain. Recent reports indicate that identification of foamy alveolar casts (FACs) with Papanicolaou's (Pap) stain may provide a sensitive and less complicated way of making the diagnosis. To confirm these observations, results on a series of 318 BALs were reviewed. PC was identified on 65 (20%) specimens from 54 patients. Pap stains and GMS stains were positive on 56 (86%) of these BALs. Pap stains were positive on seven (11%) specimens that had negative GMS stains. PC was later confirmed on these specimens by other methods. Only two (3%) BALs had positive GMS stains and negative Pap stains. The results of this study confirm other reports that show that PC can be sensitively diagnosed with the Pap stain. The authors suggest that routine special stains for PC are unnecessary on BALs.
Assuntos
Líquido da Lavagem Broncoalveolar/microbiologia , Pneumocystis/isolamento & purificação , Pneumonia por Pneumocystis/diagnóstico , Coloração e Rotulagem , Líquido da Lavagem Broncoalveolar/citologia , Feminino , Humanos , Metenamina , Pneumonia por Pneumocystis/patologia , Coloração e Rotulagem/métodosAssuntos
Corpo Carotídeo/metabolismo , Regulação da Expressão Gênica , Hipóxia/genética , Proteínas do Tecido Nervoso/genética , RNA Mensageiro/biossíntese , Técnica de Subtração , Animais , Ligação Competitiva , Hipóxia/metabolismo , Masculino , Proteínas do Tecido Nervoso/biossíntese , Reação em Cadeia da Polimerase , RNA Mensageiro/genética , RatosRESUMO
BRCA1 is a breast and ovarian cancer susceptibility gene. An inferred germline regulatory mutation was previously reported in the BRCA1-linked kindred K2035, based on the absence of transcripts from the BRCA1 allele associated with the cancer susceptibility haplotype. In this study, the promoter region of BRCA1 was examined in individuals from K2035 for evidence of a mutation which could halt transcription. Evaluation of a polymorphism located within intron 2 of BRCA1 gave results consistent with the presence of a large deletion in K2035 mutation carriers. Southern blot analysis identified unique restriction fragments which occurred as a result of a 14 kb deletion that removed both of BRCA1's transcription start sites (exons 1a and 1b) as well as exon 2. Sequencing indicated that unequal crossover between Alu repeats was the likely cause of the deletion. Similar deletions may be responsible for other reported inferred regulatory mutations, as well as unidentified mutations in families linked to BRCA1.
Assuntos
Proteína BRCA1/genética , Neoplasias da Mama/genética , Genes Supressores de Tumor/genética , Regiões Promotoras Genéticas/genética , Deleção de Sequência , Adulto , Southern Blotting , Troca Genética , Primers do DNA , Sondas de DNA , Feminino , Haplótipos , Humanos , Íntrons/genética , Pessoa de Meia-Idade , Mutação , Hibridização de Ácido Nucleico , Reação em Cadeia da Polimerase , Sequências Repetitivas de Ácido Nucleico , Mapeamento por RestriçãoRESUMO
The q21 region of chromosome 17 contains the gene BRCA1, which is involved in familial early-onset breast and ovarian cancers. A physical map of a region that extends from a distal boundary of the BRCA1 region, D17S78, to GP2B has been constructed. The map consists of 30 STSs, including 2 new short tandem repeat polymorphic markers. The contig is composed of a mixture of 7 YACs, 5 P1 plasmids, and 14 cosmids and was ordered by STS-content mapping.
Assuntos
Cromossomos Humanos Par 17 , Proteínas de Neoplasias/genética , Fatores de Transcrição/genética , Proteína BRCA1 , Sequência de Bases , Neoplasias da Mama/genética , Mapeamento Cromossômico , Cromossomos Artificiais de Levedura , Clonagem Molecular , Cosmídeos , Primers do DNA , Marcadores Genéticos , Humanos , Dados de Sequência Molecular , Plasmídeos , Reação em Cadeia da PolimeraseRESUMO
BRCA1, a breast and ovarian cancer susceptibility locus, has been isolated and maps to 17q21. A physical map of the BRCA1 region which extended from the proximal boundary at D17S776 to the distal boundary at D17S78 was constructed and consists of 51 sequence tagged sites (STSs) from P1 and YAC ends, nine new short-tandem repeat (STR) polymorphic markers, and eight identified genes. The contig, which spans the estimated 2.3 Mb region, contains 29 P1s, 11 YACs, two BACs, and one cosmid. Based on key recombinants in two linked families, BRCA1 was further localized to a region bounded by D17S1321 on the proximal side and D17S1325 on the distal side. Within this estimated 600 kb region, the contig was composed completely of P1s and BACs ordered by STS-content mapping and confirmed by DNA restriction fragment fingerprinting.
Assuntos
Neoplasias da Mama/genética , Mapeamento Cromossômico , Sequência de Bases , Mapeamento Cromossômico/métodos , Clonagem Molecular , Eletroforese em Gel de Campo Pulsado , Vetores Genéticos , Humanos , Dados de Sequência Molecular , Mapeamento por RestriçãoRESUMO
BACKGROUND: We aimed to find out the proportion of breast cancers in Ashkenazi Jewish women attributable to the frameshift mutation at position 185 involving the deletion of adenine and guanine (185delAG) in the breast cancer gene BRCA1. METHODS: We studied 107 Ashkenazi Jewish women with breast cancer seen at medical oncology and genetic counseling clinics in New York over a three and a half year period beginning in 1992. 80 of the women were diagnosed before age 42 years; the other 27 were diagnosed between 42 and 50 years and had a positive family history. Genomic DNA testing by PCR amplification was done to identify any 185delAG mutations of the BRCA1 gene. FINDINGS: Of the 80 women diagnosed before the age of 42 years, 16 (20%, 95% CI 11.2-28.8) were heterozygous for the mutation. All 16 women had at least one first-degree or second-degree relative with breast or ovarian cancer. Of 27 probands diagnosed with breast cancer between the ages of 42 and 50 years who had at least one first-degree relative affected with breast or ovarian cancer, 8 (30%, 95% CI 12-47) had 185delAG mutations. INTERPRETATION: These data suggest that screening for the 185delAG mutation may be useful in genetic counselling of these women where options for detection and prevention of possible cancers can be discussed.
Assuntos
Neoplasias da Mama/genética , Mutação em Linhagem Germinativa , Judeus , Adulto , Sequência de Bases , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/etnologia , DNA de Neoplasias/genética , Feminino , Humanos , Pessoa de Meia-Idade , Dados de Sequência Molecular , Reação em Cadeia da PolimeraseRESUMO
In this paper we present linkage results from the analysis of 18 Utah breast cancer kindreds, for three 17q markers. Four kindreds had LOD scores greater than 1.0 for at least one of the marker loci. One of these kindreds has a LOD score of 6.07 with D17S579, and we believe it to be the most informative 17q family reported to date. Among the kindreds which appear unlinked to 17q were an early-onset breast cancer family, a large breast-ovarian family, and a kindred with mixed age at onset. Analysis of individual recombinants in the linked families localizes the BRCA1 gene between THRA1 and D17S579 (Mfd188). A comparison of the Cancer and Steroid Hormone Study (CASH) model and a model which assumes a rare dominant susceptibility locus with low penetrance and no phenocopies stresses the difficulties in assessing linkage if the assumptions of the CASH model in terms of age at onset of breast cancer are not appropriate for the BRCA1 locus. A hypothetical breast cancer pedigree is used to calculate gene carrier probabilities under the CASH model, thereby illustrating some of our concerns regarding the use of this model to detect and exclude 17q linkage in breast cancer families.